Evidence map›Paper›PMID 42014381›Full record

ArticleTranslational psychiatry2026

Subanesthetic doses of ketamine to rats and monkeys rapidly increases radioligand binding in brain to phosphodiesterase-4, an indirect marker of cAMP.

Paul A Parcon, Amanda Bardhoshi, Amanda Olsen-Dufour, Raven Cureton, Susovan Jana, Cheryl L Morse, Ioline D Henter, Julia Totis, Adrian E Jenson, Matilah T Pamie-George and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Paul A ParconMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. paul.parcon@nih.gov.ORCID http://orcid.org/0000-0002-3606-3041
Amanda BardhoshiMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Amanda Olsen-DufourMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Raven CuretonMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Susovan JanaMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9910-347X
Cheryl L MorseMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Ioline D HenterMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Julia TotisMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0009-0003-9111-0546
Adrian E JensonMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Matilah T Pamie-GeorgeMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0009-0008-0176-8114
Jeih-San LiowMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Sami S ZoghbiMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Shawn WuMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
Victor W PikeMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9032-2553
Robert B InnisMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Clinical Evaluation of PET RadiotracersZIAMH002852 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2009 to 2025
$48.6M
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) ZiAMH002793U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) ZIAMH002793U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) ZIAMH002852
6 · The paper itself

Abstract

The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is a robust, rapid-acting antidepressant whose molecular effects have not been fully elucidated. Phosphodiesterase-4 (PDE4), which terminates cyclic adenosine monophosphate (cAMP) activity, may underlie antidepressant response. In particular, previous studies found that whole brain binding of the positron emission tomography (PET) radioligand [

Indexed as

Antidepressive AgentsBrainCyclic AMPCyclic Nucleotide Phosphodiesterases, Type 4KetamineAnimalsCarbon RadioisotopesMacaca mulattaMalePhosphodiesterase 4 InhibitorsPositron-Emission TomographyPyrazolesPyridazinesRatsRats, Sprague-DawleyRolipram1-(2-fluoro-4-(1H-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-oneAntidepressive AgentsCarbon RadioisotopesCyclic AMPCyclic Nucleotide Phosphodiesterases, Type 4KetaminePhosphodiesterase 4 InhibitorsPyrazolesPyridazinesRolipram

Identifiers

PMID42014381
PMCPMC13233975

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.